Genetic and Environmental Risk Factors for PSP

PSP 的遗传和环境风险因素

基本信息

  • 批准号:
    7096316
  • 负责人:
  • 金额:
    $ 62.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-15 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Progressive supranuclear palsy (PSP) is a sporadic tauopathy with unknown cause. The H1 tau haplotype is implicated in its etiology; however, it is also present in 60% of normal controls. This, coupled with late symptom onset, indicates that genetics alone does not cause PSP. Support for the environmental factor hypothesis stems from animal models and the observed association between PSP and exposure to mitochondrial complex I inhibitors (i.e., acetogenins), which are neurotoxic to dopaminergic neurons. Impaired metabolism in PSP mitochondria and oxidative injury in affected brain areas also support this hypothesis. Hence, genes and environment may both play a role either alone or through their interactions. This application will determine: 1) if there is an association between PSP and the HI/HI genotype, specific HI sub-haplotypes, alpha-synuclein polymorphisms or parkin gene deficits, or if there are gene-gene interactions; 2) if there is an association between PSP occupational and/or environmental chemical exposures functionally or structurally similar to rotenone/acetogenins; and 3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Previous case-control studies have been inconclusive because of limitations in size, scope, or structure. This is the first adequately powered series of PSP cases with matched controls that has the necessary infrastructure to address our hypotheses and explore gene-environmental interactions. As a result, it will help resolve controversies concerning the cause(s) of PSP and will stimulate new avenues of pathogenesis research and prophylactic therapies. Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the complex etiology of PSP. The use of the NINDS cell repository for genetic banking will also allow DNA sample sharing with other investigators.
描述(由申请人提供):进行性核上性麻痹(PSP)是一种原因不明的散发性tau蛋白病。H1 tau单倍型与其病因有关;然而,它也存在于60%的正常对照中。这一点,加上后期症状发作,表明遗传本身并不导致PSP。对环境因素假说的支持源于动物模型和观察到的PSP与暴露于线粒体复合物I抑制剂之间的关联(即,acetogenins),其对多巴胺能神经元具有神经毒性。PSP线粒体的代谢受损和受影响脑区的氧化损伤也支持这一假设。因此,基因和环境都可以单独或通过它们的相互作用发挥作用。此应用程序将确定:1)PSP与HI/HI基因型、特定HI亚单倍型、α-突触核蛋白多态性或parkin基因缺陷之间是否存在关联,或者是否存在基因-基因相互作用; 2)PSP职业和/或环境化学品暴露之间是否存在功能或结构上类似于鱼藤酮/乙酮的关联;(3)PSP发病前是否伴有高血压或创伤性脑损伤。为了解开PSP的复杂病因,这项病例对照多中心研究涉及500例PSP病例,500例年龄/性别匹配的初级对照,以及500例用于遗传确认的次级对照。以前的病例对照研究由于规模、范围或结构的限制而没有结论。这是第一个有足够动力的PSP病例系列,具有匹配的对照,具有必要的基础设施来解决我们的假设并探索基因-环境相互作用。因此,它将有助于解决有关PSP病因的争议,并将刺激发病机制研究和预防治疗的新途径。了解PSP的病因也可能有助于解释其他tau蛋白病如阿尔茨海默病的原因。这个由运动障碍专家、流行病学家、遗传学家、生物统计学家、工业药物学家和毒理学家组成的多学科团队非常适合解开PSP的复杂病因。使用NINDS细胞库进行基因库也将允许与其他研究人员共享DNA样本。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Irene Litvan其他文献

Irene Litvan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Irene Litvan', 18)}}的其他基金

Real-Time L-Dopa Monitoring for Improved Management of Parkinson Disease
实时左旋多巴监测可改善帕金森病的管理
  • 批准号:
    10056836
  • 财政年份:
    2020
  • 资助金额:
    $ 62.89万
  • 项目类别:
Second International Brainstorming Meeting on Parkinson Disease: Nosology
第二届帕金森病国际头脑风暴会议:疾病分类学
  • 批准号:
    7485398
  • 财政年份:
    2008
  • 资助金额:
    $ 62.89万
  • 项目类别:
Genetic and Environmental Risk Factors for PSP
PSP 的遗传和环境风险因素
  • 批准号:
    7870302
  • 财政年份:
    2006
  • 资助金额:
    $ 62.89万
  • 项目类别:
Genetic and Environmental Risk Factors for PSP
PSP 的遗传和环境风险因素
  • 批准号:
    7631302
  • 财政年份:
    2006
  • 资助金额:
    $ 62.89万
  • 项目类别:
Genetic and Environmental Risk Factors for PSP
PSP 的遗传和环境风险因素
  • 批准号:
    7457789
  • 财政年份:
    2006
  • 资助金额:
    $ 62.89万
  • 项目类别:
Genetic and Environmental Risk Factors for PSP
PSP 的遗传和环境风险因素
  • 批准号:
    7259458
  • 财政年份:
    2006
  • 资助金额:
    $ 62.89万
  • 项目类别:

相似海外基金

Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Research Grant
Development of a humanised delivery system for interleukin 2 to treat traumatic brain injury
开发白细胞介素2人源化递送系统来治疗创伤性脑损伤
  • 批准号:
    MR/X029166/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Research Grant
Who is Caring for the Caregiver? Understanding Quality of Life and Mental Health Outcomes in Caregivers of Persons with Brain Injury
谁在照顾看护者?
  • 批准号:
    492369
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Operating Grants
A PROGRESS-Driven Approach to Cognitive Outcomes after Traumatic Brain Injury: Advancing Equity, Diversity, and Inclusion through Knowledge Synthesis and Mobilization
创伤性脑损伤后认知结果的进步驱动方法:通过知识合成和动员促进公平、多样性和包容性
  • 批准号:
    492338
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Operating Grants
Advancing equity in traumatic brain injury care: A stakeholder-informed meeting on screening for traumatic brain injury in underserved populations
促进创伤性脑损伤护理的公平性:关于在服务不足的人群中筛查创伤性脑损伤的利益相关者知情会议
  • 批准号:
    487815
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Miscellaneous Programs
Targeting Ryanodine Receptor 2 for Treating Neonatal Hypoxic-ischemic Brain Injury (HIBI)
靶向 Ryanodine 受体 2 治疗新生儿缺氧缺血性脑损伤 (HIBI)
  • 批准号:
    488816
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Operating Grants
Blood biomarkers to detect brain injury due to intimate partner violence
血液生物标志物可检测亲密伴侣暴力造成的脑损伤
  • 批准号:
    486950
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
    Operating Grants
Neuromodulation for impulsivity and suicidality in Veterans with mildtraumatic brain injury and common co-occurring mental health conditions
神经调节对患有轻度脑损伤和常见并发心理健康状况的退伍军人的冲动和自杀倾向
  • 批准号:
    10640567
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
Combinatorial Neuroprotective Strategies for Preterm Brain Injury
早产儿脑损伤的组合神经保护策略
  • 批准号:
    10798705
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
Oxidative Lipidomics in Pediatric Traumatic Brain Injury
氧化脂质组学在小儿创伤性脑损伤中的应用
  • 批准号:
    10844023
  • 财政年份:
    2023
  • 资助金额:
    $ 62.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了